Treatment of these pancreatic KRAS tumors has proven especially difficult due to dense desmoplastic stroma which denies effector immune cells or therapeutics access to the tumor, creating an immunosuppressive microenvironment and tumor that is invulnerable to immune checkpoint inhibition. Here, KRAS is linked to neoplasm.